Osaka, Japan, Japan · Est. 1781 · 47,000 employees
Takeda is a global biopharmaceutical company focused on developing treatments in oncology, gastroenterology, neuroscience, and rare diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 16 drugs with upcoming expirations
Pipeline
By Phase
34 drugs in development
By Therapeutic Area
top 6
R&D Momentum
84/100
Pipeline Velocity
56/100
Trial Completion Rate
85/100
Pipeline Concentration
12/100
Pipeline Freshness
72/100
Strategic Signals
Activity
Last 14 days
A Global, Multicenter, Single-arm, Matched External Control Study of Intrathecal SHP611 in Subjects With Late Infantile Metachromatic Leukodystrophy
A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
General Use-results Survey of OBIZUR for I.V. Injection (All-case Surveillance)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants With Chronic Primary Immune Thrombocytopenia
A Phase 3, Open-label, Multicenter Continuation Trial to Evaluate the Long-term Safety and Efficacy of Mezagitamab Subcutaneous Injection in Adults With Chronic Primary Immune Thrombocytopenia
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
A Double-blind, Placebo-Controlled, Randomized Withdrawal Trial to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1)
Specified Drug Use Surveillance of FIRAZYR Subcutaneous Injection 30mg Syringe for Pediatric Subjects With Hereditary Angioedema (All-Case Investigation)
An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Dual Targeted Therapy With Vedolizumab Intravenous (IV) and Adalimumab Subcutaneous (SC) or Vedolizumab IV and Ustekinumab IV/SC in Moderate to Severe Crohn's Disease (CD)
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors
Details
Company Overview
$55.0B
Mkt Cap
$32.0B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
Gattex Kit — GATTEX KIT
Application NDA203441 (NDA)
Omontys — OMONTYS
Application NDA202799 (NDA)
Brintellix — TRINTELLIX
Application NDA204447 (NDA)
Lialda — DELZICOL
Application NDA204412 (NDA)
Nesina — NESINA
Application NDA022271 (NDA)
Vyvanse — VYVANSE
Application NDA021977 (NDA)
Fosrenol — FOSRENOL
Application NDA204734 (NDA)
Entyvio — ENTYVIO
Application BLA125476 (BLA)
Ninlaro — NINLARO
Application NDA208462 (NDA)
Prevacid — LANSOPRAZOLE
Application NDA208025 (NDA)
Dexilant — DEXILANT SOLUTAB
Application NDA208056 (NDA)
Alunbrig — ALUNBRIG
Application NDA208772 (NDA)
Vyvanse — VYVANSE
Application NDA208510 (NDA)
Resotran — MOTEGRITY
Application NDA210166 (NDA)
Iclusig — ICLUSIG
Application NDA203469 (NDA)
Livtencity — LIVTENCITY
Application NDA215596 (NDA)
Exkivity — EXKIVITY
Application NDA215310 (NDA)
Elunate — FRUZAQLA
Application NDA217564 (NDA)
Entyvio — ENTYVIO
Application BLA761133 (BLA)
Vyvanse — ARYNTA
Application NDA219847 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)